Focused On-demand Library for Plasma membrane calcium-transporting ATPase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Plasma membrane calcium ATPase isoform 2; Plasma membrane calcium pump isoform 2

Alternative UPACC:

Q01814; O00766; Q12994; Q16818


Plasma membrane calcium-transporting ATPase 2, also known as Plasma membrane calcium ATPase isoform 2, plays a pivotal role in maintaining basal intracellular Ca(2+) levels in specialized cells. It is crucial for the functioning of cerebellar circuits, vestibular and cochlear systems, facilitating fast neuronal Ca(2+) dynamics, and is essential in hearing and balance. This protein mediates presynaptic Ca(2+) efflux and contributes to motor learning by controlling Ca(2+) clearance rates.

Therapeutic significance:

The protein's involvement in Deafness, autosomal dominant, 82, a form of sensorineural hearing loss, underscores its therapeutic significance. Understanding the role of Plasma membrane calcium-transporting ATPase 2 could open doors to potential therapeutic strategies for hearing loss and balance disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.